28.05.2015
- AbbVie has completed the acquisition of Pharmacyclics, a deal the Chicago-based US drugmaker says enhances its scientific and commercial presence in oncology. As a wholly owned...
18.05.2015
- The pharmaceuticals and life sciences sectors saw 35 mergers and acquisitions worth $166.3 billion in the first three months of 2015, a value that eclipsed transactions from all of...
20.03.2015
- AbbVie is expanding an existing site in Puerto Rico at a cost of $30 million, adding to its capacity for biotechnology. The proposed expansion will take place in AbbVie's site...
05.03.2015
- US drugmaker AbbVie has reached final agreement to acquire compatriot Pharmacyclics and the company's flagship asset Imbruvica (ibrutinib), which it describes as "a highly...
06.02.2015
- US regulators intend to rescind the "breakthrough therapy" designation for Merck & Co's hepatitis C combination treatment, a decision that could delay approval of the product by...
20.01.2015
- Europe, where about 15 million people are believed to be infected with hepatitis C, could become the next battleground between US drugmakers Gilead Sciences and AbbVie in their...
19.01.2015
- The largest US health insurer, Aetna, has negotiated a discount for Gilead Sciences' hepatitis C treatment regime and said it plans to offer this as a preferred choice for its...
23.12.2014
- The largest pharmacy benefit manager in the US, Express Scripts, has negotiated a cheaper price from AbbVie for its Viekira Pak hepatitis C treatment approved by the US Food and...
